Table 3. Comparison of characteristics before and after PSM between the two groups.
| Feature | Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| Immunotherapy (n=16) | Chemotherapy (n=32) | P | Immunotherapy (n=10) | Chemotherapy (n=10) | P | ||
| Gender, n (%) | 0.131 | 1.000 | |||||
| Male | 10 (62.5) | 12 (37.5) | 5 (50.0) | 4 (40.0) | |||
| Female | 6 (37.5) | 20 (62.5) | 5 (50.0) | 6 (60.0) | |||
| Median age, years [range] | 61 [35–77] | 60.5 [44–75] | 0.991 | 62 [35–77] | 57.5 [47–70] | 0.766 | |
| Smoking, n (%) | 0.110 | 0.650 | |||||
| Former/ever smoker | 8 (60.0) | 8 (22.6) | 5 (50.0) | 3 (30.0) | |||
| Mutation type, n (%) | 0.005 | 1.000 | |||||
| EGFR ex20ins | 5 (31.2) | 24 (75.0) | 3 (30.0) | 3 (30.0) | |||
| HER2 ex20ins | 11 (68.8) | 8 (25.0) | 7 (70.0) | 7 (70.0) | |||
| PS score, n (%) | 1.000 | 1.000 | |||||
| 0–1 | 15 (93.8) | 31 (96.9) | 10 (100.0) | 10 (100.0) | |||
| ≥2 | 1 (6.3) | 1 (3.1) | 0 (0.0) | 0 (0.0) | |||
| PD-L1 expression, n (%) | 0.310 | 0.656 | |||||
| ≥1% | 6 (37.5) | 7 (21.9) | 4 (40.0) | 6 (60.0) | |||
| <1% or unevaluable | 10 (62.5) | 25 (78.1) | 6 (60.0) | 4 (40.0) | |||
| Brain metastasis, n (%) | 6 (37.5) | 10 (31.3) | 0.750 | 3 (30.0) | 4 (40.0) | 1.000 | |
| Liver metastasis, n (%) | 2 (12.5) | 3 (9.4) | 1.000 | 2 (20.0) | 1 (10.0) | 1.000 | |
PSM, propensity score matching; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; PS, Performance Status; PD-L1, programmed cell death-ligand 1.